ArticlePloS one2026
Formulation of 5-fluorouracil loaded chitosan-based nanoparticles and evaluation of its cytotoxic effects against MCF-7 human breast cancer cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a major global health issue with a high mortality rate. In breast cancer treatment, chemotherapeutic drugs have a toxic effect on both cancerous and healthy cells which can lead to severe adverse effects and chemoresistance. Chitosan-based nanoparticles (NPs) have been reported to improve cellular drug delivery, thereby remediating the chemoresistance of anticancer drugs. The purpose of this research was to formulate 5-fluorouracil (5-FU) loaded chitosan nanoparticles. 5-FU nanoparticles were synthesized using ionic gelation technique which is based on the ionic interaction of positively charged chitosan and negatively charged tripolyphosphate that serves as a cross linker. The formulated nanoparticles were evaluated using UV spectrophotometer, Fourier-transform infrared spectroscopy, X-ray diffraction, Scanning Electron Microscopy. The cytotoxicity study was done using MTT assays. FTIR analysis revealed complete drug encapsulation of the nanoparticles via intermolecular interactions. The result of the XRD analysis showed that the drug was crystalline in the nanoparticle distribution. The SEM analysis confirmed the spherical morphology and structure. The synthesized nanoparticles had a mean particle size of 218.62 nm, zeta potential values of ≤+32.18 mV, Pdi values ranging from 0.14-0.29 and encapsulation efficiency results of ≤37.54%. The drug release mechanism was via Fickian diffusion. MTT analysis showed a time-dependent cytotoxic effect of 5-FU nanoparticles on breast cancer (MCF-7) cell lines after 72 h. This study confirmed that formulation of 5-FU into nanoparticles is a promising approach for sustained release and site-specific anticancer drug delivery which can potentially minimize the systemic side effects and improve treatment outcomes in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.